Oct. 30 at 9:19 PM
$INVA This is next, we hit
$CRNX and
$GKOS 25 % plus. Do your DD.
PDUFA Date: Dec 15, 2025
Zoliflodacin — Oral antibiotic for gonorrhea
FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority).
Market Impact: Medium–large public health value, smaller direct commercial revenue.
U.S. gonorrhea cases ~700k/year (CDC).
New oral option = government/NGO contracts, global demand, less private pricing power.
Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.
